COMPUTEX 2025 Gathers Global Tech Minds to Explore AI-Driven Industrial Evolution

TAIPEI, May 19, 2025 /PRNewswire/ -- COMPUTEX TAIPEI 2025, one of the global iconic exhibitions for AI and innovation, will officially open tomorrow, May 20, at the Taipei Nangang Exhibition Center Halls 1 and 2. The event brings together 1,400 exhibitors from 34 countries and regions to showcase their innovations across 4,800 booths. This year, COMPUTEX continues to lead the global tech ecosystem, inviting major industry players—NVIDIA, Qualcomm, Foxconn, MediaTek, NXP, and other tech giants to deliver keynote speeches. Leading research firm Gartner is also invited to provide in-depth insights into AI technologies and industry trends, collectively exploring cutting-edge innovation and emerging business opportunities.
According to Gartner, global spending on generative AI will reach US$ 644 billion in 2025. Companies are investing billions annually to improve the scale, performance, and reliability of generative AI models. AI is expected to become a standard built-in feature in future consumer electronics. In response to this AI-driven economic transformation, COMPUTEX 2025 is themed "AI Next" and focuses on AI & Robotics, Next-Gen Tech, and Future Mobility, echoing global trends in AI innovation and industrial transformation.
James Huang, Chairman of Taiwan External Trade Development Council (TAITRA), remarked, "AI is transforming industries at an unprecedented pace—from algorithmic breakthroughs to broader accessibility. Taiwan, with its leadership in semiconductors and innovation, is driving this global shift. COMPUTEX 2025 spotlights AI & robotics, next-gen technologies, and future mobility as the cornerstones of the next wave of innovation."
Paul S.L. Peng, Chairman of the Taipei Computer Association, said: "Taiwan stands strong in the AI era with its world-class semiconductor supply chain, cutting-edge software-hardware integration, and real-world solutions for challenges like smart aging and labor resilience."
COMPUTEX Keynotes: Industry Titans to Lead the Conversation and Explore AI-Driven Industry Transformation
The COMPUTEX Keynote series will feature world-leading tech executives from around the world, including Jensen Huang, CEO of NVIDIA; Cristiano Amon, CEO of Qualcomm; Young Liu, Chairman of Foxconn Technology Group; Dr. Rick Tsai, Vice Chairman and CEO of MediaTek; Jens Hinrichsen, EVP of NXP, and more. These industry heavyweights will provide multi-perspective insights on AI applications in communications, automotive, smart manufacturing, and edge computing, offering the latest breakthroughs and charting the future direction of global industries.
COMPUTEX Forum: A Deep Dive into the AI Ecosystem
The COMPUTEX Forum will spotlight the development of the AI ecosystem through two focused sessions:
Morning session: Industry experts from NVIDIA, Google DeepMind, Texas Instruments, Advantech, and others will discuss business opportunities in AI robotics and edge computing, as well as how these technologies are reshaping industries.
Afternoon session: Speakers from Arm, Intel, Adobe, Cadence, and other tech-leading brands will share the next evolution of generative AI applications and real-world use cases. Additionally, leading companies, including bp Castrol, Infineon, Seagate, Schneider Electric, and Compal, will present highly efficient AI data center solutions, addressing the growing demands for AI computing power and data capacity.
InnoVEX 2025 Upgraded: Asia's Innovation Hub for Startups
COMPUTEX's InnoVEX—Asia's premier innovation and startup platform—returns with record momentum. Nearly 450 startup teams from 24 countries will participate. Ten countries—including Belgium, France, Thailand, Israel, Japan, and more—will feature national pavilions. Global leading accelerators and venture capital firms like NVIDIA Inception, Garage+, and StarFab will connect with startups to foster collaboration and cross-border growth. The InnoVEX Forum will feature talks by leaders from AWS, Qualcomm, Google Cloud, NVIDIA, and more, sharing insights into AI innovation and trends. Other show events, such as startup pitch competitions and Global Demo Day, will further highlight the dynamic international startup scene.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Korea Herald

17 hours ago

• Korea Herald

[Bio USA] SK Biopharmaceuticals CEO highlights resilience, open innovation amid global shifts

Korea Herald correspondent BOSTON — SK Biopharmaceuticals CEO Lee Dong-hoon underscored the company's preparedness for potential US tariff changes and emphasized the critical role of open innovation in shaping the future of global pharmaceuticals. 'We've weathered volatility in our share price over the past year, but the impact of potential price cuts has been minimal,' Lee said Thursday during a press conference on the sidelines of the 2025 Bio USA. 'Our direct-to-market sales model remains fundamentally solid.' He recalled a particularly tense moment earlier this year when shifting US tariff policies posed logistical challenges. In April, the company rushed to transport finished products from Canada into the US before a new tariff deadline. 'When the final truck finally cleared customs, everyone burst into applause,' he recounted. To prevent such risks from recurring, the company now assembles finished products in Canada and ensures shipments cross the border ahead of any policy changes. Looking ahead, SK Biopharmaceuticals is evaluating Puerto Rico as a potential US-based manufacturing site, leveraging its status as a US territory and pharmaceutical hub. 'Canada is cost-effective for now, but we're preparing for every scenario,' Lee said, noting the company's tariff risk is now 'close to zero' for the year. Lee also expressed confidence in the company's long-term growth. 'We've already announced our goal to hit 1 trillion won ($728 million) in sales by 2029, and we're on track,' he said, citing consistent profitability since last year. A cornerstone of SK Biopharmaceuticals' strategy is open innovation. Instead of relying solely on internal research and development, the company is partnering with universities, biotech firms and research institutions. 'Major global pharmaceutical firms are moving away from in-house basic research, and so are we. When you can collaborate and generate results at a fraction of the cost, your possibilities expand," he explained. The CEO emphasized the importance of tapping into underutilized technologies at US universities and biotech startups to diversify the company's pipeline, moving beyond its core focus on epilepsy into areas like oncology. Artificial intelligence is another major focus area. Lee highlighted the company's work on EEG-based seizure prediction models in collaboration with European and South American partners, along with AI algorithm development trials currently underway in Korea. 'AI is no longer optional. It's essential in every part of the business,' he said. One standout partnership is with PhnyX Lab, whose AI-driven automation of clinical documentation significantly reduced paperwork. 'Even our US team, which was initially skeptical, was blown away,' Lee said, calling the shift 'Copernican' in scale for how it will reduce time and cost. The CEO also outlined plans to build a global digital platform for epilepsy patients — a space where patients and physicians can share experiences and insights. 'It's not about selling drugs,' he clarified. 'It's about collecting data to inform AI-powered marketing, drug development and clinical trial design.' The company is looking three to five years ahead, aiming to build an ecosystem where shared data drives innovation across functions. In the US, SK Biopharmaceuticals is intensifying its engagement with health care providers. Lee has personally met with dozens of physicians this year, aiming for 100 meetings, to gather insights that will shape lifecycle strategies such as patent extensions, expanded indications and new formulations like IV delivery. Meanwhile, SK Biopharmaceuticals has invested in targeted TV and YouTube campaigns for its flagship epilepsy drug, Xcopri (cenobamate). Its 'Road to Reduction' campaign drew 9.37 million views in just one month, signaling the brand's growing visibility and leadership in the epilepsy treatment market.

Korea Herald

20 hours ago

• Korea Herald

HD Hyundai partners with Edison Chouest Offshore to build LNG dual-fuel container ships

Korean shipbuilding giant HD Hyundai announced Sunday that it has signed a strategic and comprehensive partnership with US-based Edison Chouest Offshore to jointly build LNG dual-fuel container ships in the United States. This initiative follows HD Hyundai's recent agreements with major US defense firms and academic institutions. The signing ceremony took place on Thursday at ECO's headquarters in New Orleans, Louisiana, attended by key officials from both companies. Under the deal, HD Hyundai and ECO plan to jointly construct medium-sized container ships at ECO's shipyards by 2028. HD Hyundai will provide support for ship design, equipment procurement and construction technology. It also plans to produce and supply ship blocks and invest in related technological assets. Both companies are exploring expanded cooperation in additional vessel types and port cranes, which are considered critical for US national security. ECO operates five shipyards across the US and manages a fleet of 300 offshore support vessels, positioning it as a major player in the OSV sector. The partnership follows a sluggish period for US shipbuilding, with domestic firms receiving orders for only three 3,600 twenty-foot equivalent unit container ships from 2022 to 2024, according to shipping market analysis firm Clarkson Research. 'The United States is a strong ally and an important business partner,' an HD Hyundai spokesperson said. 'Through this collaboration, we aim to support the revival of its shipbuilding industry and bolster its national security.'

Korea Herald

2 days ago

• Korea Herald

US may target Samsung, Hynix, TSMC operations in China, sources say

The US Department of Commerce is considering revoking authorizations granted in recent years to global chipmakers Samsung, SK Hynix and TSMC, making it more difficult for them to receive US goods and technology at their plants in China, according to people familiar with the matter. The chances of the United States withdrawing the authorizations are unclear. But with such a move, it would be harder for foreign chipmakers to operate in China, where they produce semiconductors used in a wide range of industries. A White House official said the US was "just laying the groundwork" in case the truce reached between the two countries fell apart. But the official expressed confidence that the trade agreement would go forward and that rare earths would flow from China, as agreed. "There is currently no intention of deploying this tactic," the official said. "It's another tool we want in our toolbox in case either this agreement falls through or any other catalyst throws a wrench in bilateral relations." Shares of US chip equipment makers that supply plants in China fell when the Wall Street Journal first reported the news earlier on Friday. KLA Corp dropped 2.4 percent, Lam Research fell 1.9 percent and Applied Materials sank 2 percent. Shares of Micron, a major competitor to Samsung and SK Hynix in the memory chip sector, rose 1.5 percent. A TSMC spokesman declined comment. Samsung and Hynix did not immediately respond to requests for comment. Lam Research, KLA and Applied Materials did not immediately respond, either. In October 2022, after the United States placed sweeping restrictions on US chipmaking equipment to China, it gave foreign manufacturers like Samsung and Hynix letters authorizing them to receive goods. In 2023 and 2024, the companies received what is known as Validated End User status in order to continue the trade. A company with VEU status is able to receive designated goods from a US company without the supplier obtaining multiple export licenses to ship to them. VEU status enables entities to receive US-controlled products and technologies "more easily, quickly and reliably," as the Commerce Department website puts it. The VEU authorizations come with conditions, a person familiar with the matter said, including prohibitions on certain equipment and reporting requirements. 'Chipmakers will still be able to operate in China," a Commerce Department spokesperson said in a statement when asked about the possible revocations. "The new enforcement mechanisms on chips mirror licensing requirements that apply to other semiconductor companies that export to China and ensure the United States has an equal and reciprocal process.' Industry sources said that if it became more difficult for US semiconductor equipment companies to ship to foreign multinationals, it would only help domestic Chinese competitors.